Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dental amalgams

This article was originally published in The Gray Sheet

Executive Summary

FDA is in the process of reviewing over 750 comments relating to the proposed reclassification of dental amalgams, CDRH Director David Feigal testifies during Nov. 14 hearing before the House Government Reform Committee. Earlier this year, FDA reopened the comment period for a Feb. 20 proposed rule that would classify encapsulated amalgam and dental mercury as Class II (1"The Gray Sheet" July 22, 2002, p. 10). FDA, NIH and CDC plan further review of 1993 findings showing no definitive evidence linking the placement of amalgams to onset of systematic disease, according to Feigal...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts